SCHEMBL6440847

SCHEMBL6440847

COCCN1Cc2cc(OC)ccc2C1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 5/20 0.51
ALDH1A1 P00352 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
AOC3 Q16853 2/20 0.49
PARP1 P09874 1/20 0.45
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
METAP1 P53582 1/20 0.43
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
DRD3 P35462 1/20 0.42
ABCB1 P08183 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.42
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15727820 0.83 PARP1 (0.45) ADAM17ALDH1A1SMN1; SMN2AOC3PARP1
SCHEMBL28612494 0.83 PARP1 (0.48) ALDH1A1SMN1; SMN2AOC3PARP1KDM4E
SCHEMBL30434602 0.83 PARP1 (0.45) ALDH1A1SMN1; SMN2AOC3PARP1PRMT5
SCHEMBL2144299 0.83 PARP1 (0.45) ALDH1A1SMN1; SMN2AOC3PARP1PRMT5
SCHEMBL8250274 0.82 KDM4E (0.60) ADAM17ALDH1A1AOC3PRMT5WDR77
SCHEMBL8547905 0.79 ADAM17 (0.53) ADAM17ALDH1A1PARP1PRMT5WDR77
SCHEMBL25225949 0.79 KDM4E (0.59) ALDH1A1SMN1; SMN2PARP1DRD2DRD3
SCHEMBL8222715 0.79 METAP1 (0.50) ADAM17PRMT5WDR77METAP1DRD2
SCHEMBL30021259 0.79 METAP1 (0.50) ADAM17PRMT5WDR77METAP1DRD2
SCHEMBL5617703 0.78 MAOB (0.54) AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1539694-A1 2,3-DIHYDRO-ISOINDOL-1-ONES WITH MAO-B INHIBITING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2005-06-15 EP disclosed
US-6846832-B2 2,3-dihydro-isoindol-1-one derivatives HOFFMAN-LA ROCHE INC. (US) 2005-01-25 US disclosed
US-20040082603-A1 2,3-Dihydro-isoindol-1-one derivatives HOFFMANN-LA ROCHE INC. 2004-04-29 US disclosed
WO-2004014856-A1 2,3-DIHYDRO-ISOINDOL-1-ONES WITH MAO-B INHIBITING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082603-A1 2,3-Dihydro-isoindol-1-one derivatives MAOB, MAOA, COMT ADAM17 1477/4885ALDH1A1 71/4885SMN1; SMN2 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.